Why does OncoSec use Immunotherapy?

Why does OncoSec use Immunotherapy?

In biotech, there are many different approaches or veins of science used, in the research and creation of potential treatments, drugs, and delivery methods. For centuries, the health industry has relied on invasive surgery and curative procedures that can have dangerous, long-term side effects for patients. However, there are some newer scientific discoveries that have allowed us to move towards more effective treatment options that are also less damaging to our bodies. One of these categories of research is that of immunotherapy: using the body against disease, instead of relying on as many non-targeted, exterior factors.

What is ImmunoPulse?

Many cancer research and treatment companies create and utilize various methods of treatment. These may be a combination of existing techniques or a new technology developed by the company itself. At OncoSec, one of our treatment methods is ImmunoPulse: a system we’re testing for the treatment of late-stage skin cancer, including merkel cell carcinoma, cutaneous T-cell lymphoma, and metastatic melanoma. With pending announcements surrounding interim data from our phase II trial for metastatic melanoma coming up soon, we would like to review a bit of the description of our ImmunoPulse treatment option currently being tested.


Real Time Web Analytics